ProKidney Corp. (PROK) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    ProKidney Corp.

    NASDAQ: PROK · Real-Time Price · USD
    2.25
    -0.05 (-2.17%)
    At close: Sep 05, 2025, 3:59 PM
    2.26
    0.45%
    After-hours: Sep 05, 2025, 06:02 PM EDT

    ProKidney Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 76K n/a n/a n/a
    Cost of Revenue
    		 n/a 3.17M 3.04M 1.98M
    Gross Profit
    		 76K -3.17M -3.04M -1.98M
    Operating Income
    		 -183.68M -151.52M -153.01M -55.11M
    Interest Income
    		 19.75M 22.08M 5.98M 2K
    Pretax Income
    		 -163.93M -129.45M -147.24M -55.11M
    Net Income
    		 -61.19M -35.47M -108.03M -55.15M
    Selling & General & Admin
    		 56.08M 44.81M 70.94M 8.86M
    Research & Development
    		 127.67M 106.71M 82.07M 46.26M
    Other Expenses
    		 n/a -3.17M n/a n/a
    Operating Expenses
    		 183.75M 148.35M 153.01M 55.11M
    Interest Expense
    		 9K 12K 215K n/a
    Selling & Marketing Expenses
    		 n/a 1.06M n/a n/a
    Cost & Expenses
    		 183.75M 151.52M 153.01M 55.11M
    Income Tax Expense
    		 -598K 6M 896K 38K
    Shares Outstanding (Basic)
    		 97.92M 61.71M 61.54M 31.89M
    Shares Outstanding (Diluted)
    		 97.92M 61.71M 61.54M 31.89M
    EPS (Basic)
    		 -0.62 -0.57 -1.76 -1.73
    EPS (Diluted)
    		 -0.62 -0.57 -1.76 -1.73
    EBITDA
    		 -158.49M -147.67M -143.99M -53.13M
    EBIT
    		 -163.92M -151.52M -147.02M -55.11M
    Depreciation & Amortization
    		 5.43M 3.85M 3.04M 1.98M

    Add to Watchlist